RecruitingPHASE2, PHASE3NCT06413654

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Studying Neuromyelitis Optica

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
Intervention: B001(drug)
Enrollment: 132 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2029

Study locations (30)

Beijing Anzhen Hospital，Capital Medical University, Beijing, China
Beijing Tiantan Hospital，Capital Medical University, Beijing, China
Beijing Tongren Hospital, Capital Medical University, Beijing, China
Peking University First Hospital, Beijing, China
The First Medical Center of PLA General Hospital, Beijing, China
The Third Medical Center of PLA General Hospital, Beijing, China
Cangzhou Central Hospital, Cangzhou, China
The Second Xiangya Hospital of Central South University, Changsha, China
Xiangya Hospital Central South University, Changsha, China
Sichuan Provincial People's Hospital, Chengdu, China
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
Guangzhou First People's Hospital, Guangzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
+15 more locations on ClinicalTrials.gov

Collaborators

Shanghai Pharmaceuticals Holding Co., Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06413654 on ClinicalTrials.gov

Other trials for Neuromyelitis Optica

Additional recruiting or active studies for the same condition.

See all trials for Neuromyelitis Optica →

← Back to all trials